Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 76.00 | |
5 mg | In stock | $ 177.00 | |
10 mg | In stock | $ 260.00 | |
25 mg | In stock | $ 506.00 | |
50 mg | In stock | $ 690.00 | |
100 mg | In stock | $ 982.00 | |
500 mg | In stock | $ 1,970.00 |
Description | Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease. |
In vitro | Copper histidine (10 lmol/L) inhibited cellular uptake of oxaliplatin mediated by Ctr1 in HEK293 cells overexpressing rat Ctr1.[1] |
Molecular Weight | 217.69 |
Formula | C6H8CuN3O2 |
CAS No. | 77280-83-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble) (1.97 mM)
DMSO: < 1mg/ml (insoluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Copper histidine 77280-83-2 inhibitor inhibit